Search clinical trials for: bevacizumab, trabectedin and carboplatin

Total 5232 results

Mario Negri Institute for Pharmacological Research
Hoffmann-La Roche; PharmaMar

Completed

Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

Ovarian Epithelial Cancer Recurrent

Italy
North Eastern German Society of Gynaecological...
PharmaMar; Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Completed

Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (COMPASS)

Quality of Life | Ovarian Cancer | Recurrent Ovarian Carcinoma

Germany
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Malignant Solid Neoplasm

United States, Puerto Rico
Mario Negri Institute for Pharmacological Research
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...

Recruiting

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (TRABEPIO)

Liposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round Cell

Italy
Italian Sarcoma Group
AstraZeneca; PharmaMar

Active, not recruiting

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2)

Advanced Soft Tissue Sarcoma

Italy
Italian Sarcoma Group
PharmaMar

Withdrawn

Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin (TRADITIONS)

Leiomyosarcoma | Liposarcoma | Synovial Sarcoma

Italy
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Ovarian Cancer
Northwestern University
National Cancer Institute (NCI)

Withdrawn

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Northwell Health

Suspended

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
University of Chicago
Genentech, Inc.

Terminated

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
Grupo Español de Investigación en Cáncer de Ovario

Completed

Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD

Ovarian Cancer

Spain
PharmaMar, Spain

Completed

Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma (YonSar)

Soft Tissue Sarcoma

Germany
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

Sarcoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma

Sarcoma

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Australia, Belgium, France, Italy, Hong Kong, Canada, Denmark, Taiwan, Russian Federation, United Kingdom, Spain, Hungary, Czech Republic, Poland, Germany, Netherlands
Jonsson Comprehensive Cancer Center
TetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaborators

Withdrawn

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma

United States
European Organisation for Research and Treatment...

Completed

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment...

Completed

Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Breast Cancer | Metastatic Breast Cancer | Progressive Breast Cancer

United States
PharmaMar

Completed

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients (NIMES-ROC)

Relapsed Ovarian Cancer

Spain, France, Italy, Belgium, Germany
Suriya Yessentayeva
Johnson & Johnson

Unknown

An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer (Renaissance)

Ovarian Cancer

Kazakhstan
PharmaMar
National Cancer Institute (NCI)

Terminated

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

Sarcoma

United States
Instituto Nacional de Cancerologia de Mexico

Recruiting

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

Lung Cancer | Sarcopenia | Toxicity

Mexico
Pfizer

Terminated

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

United States
James Elder

Completed

Carboplatin in Treating Patients With Recurrent High-Grade Gliomas

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

Tabectedin to Treat Children and Adolescents With Cancer

Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Lymphadenopathy | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Prostate Small Cell Carcinoma

United States
Annick Desjardins

Completed

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Malignant Glioma

United States
Spanish Lung Cancer Group

Completed

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab (ANGIOMET)

Nonsquamous Nonsmall Cell Neoplasm of Lung

Spain
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
IRCCS San Raffaele

Completed

Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy (PACT-18)

Pancreatic Cancer

Italy
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Reprab Study: PLD + Trabectedin Rechallenge (MITO36)

Relapsed Ovarian Cancer

Italy
Grupo Espanol de Investigacion en Sarcomas

Active, not recruiting

Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients (OLATRASTS)

Sarcoma, Soft Tissue

Spain
Mario Negri Institute for Pharmacological Research
PharmaMar; Averion International Corporation

Completed

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (INOVATYON)

Ovarian Cancer

Austria, Belgium, Norway, Spain, Finland, United Kingdom, Italy, Denmark, Germany, Netherlands, Switzerland
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Innovent Biologics (Suzhou) Co. Ltd.
WuXi CDS Clinical Research (Shanghai) Co.Ltd.

Completed

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

NSCLC

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
University of Washington
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Institut Bergonié
PharmaMar

Completed

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (TARMIC)

Soft-tissue Sarcomas

France
SCRI Development Innovations, LLC
Sanofi; Genentech, Inc.

Completed

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Non-Small Cell Lung Cancer

United States
Qingdao Central Hospital

Recruiting

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

PFS | OS

China
SCRI Development Innovations, LLC
Genentech, Inc.

Completed

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell Lung

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

Mesothelioma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States
Masonic Cancer Center, University of Minnesota
Eli Lilly and Company; Genentech, Inc.

Completed

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States

Search clinical trials for: bevacizumab, trabectedin and carboplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations